GlassScriptPhysician profile
Sean C Lalin
NPI 1275580128
$9,455.00
in general payments reported to CMS, 2019-2025
26 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $6,194 · 2021: $147 · 2022: $970 · 2023: $656 · 2024: $493 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709 · Honoraria: $38.86 · Gift: $14.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.20 |
| Honoraria | $38.86 |
| Gift | $14.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,023.32 | 2020-2022 | |
| Alcon Vision LLC | $1,608.72 | 2019-2025 | Clareon, Lensx, Clareon Panoptix Pro |
| Abbvie INC. | $289.76 | 2022-2025 | |
| Rxsight INC | $248.58 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Astellas Pharma US INC | $185.32 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $157.85 | 2022-2024 | Ic-8 Apthera Iol, Envista Mx60 Iol, Xiidra |
| Oyster Point Pharma, INC. | $116.63 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $114.61 | 2019-2025 | |
| Eyepoint US, INC. | $83.85 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $68.87 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $66.29 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $63.96 | 2019-2025 | Veritas Vision System, Catalys System |
| Amgen INC. | $61.87 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $44.09 | 2021-2022 | |
| Genentech USA, INC. | $40.81 | 2022-2023 | Vabysmo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $38.01 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $37.84 | 2019-2023 | |
| Coherus Oncology, INC. | $35.58 | 2022 | |
| Alimera Sciences, INC. | $33.74 | 2021-2022 | |
| Horizon Therapeutics Plc | $26.95 | 2023 | Tepezza |
| Sight Sciences, INC. | $26.69 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.35 | 2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $18.24 | 2025 | Iluvien |
| Ocular Therapeutix, INC. | $15.23 | 2023 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.43 | 2021 | |
| Dompe US, INC. | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Lalin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.